U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104383) titled 'VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)' on July 29.
Brief Summary: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Study Start Date: June 23
Study Type: INTERVENTIONAL
Condition:
Weight Loss
Intervention:
DRUG: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Recruitment Status: RECRUITING
Sponsor: Viking Therapeutics, Inc....